Cargando…

FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience

Cholangiocarcinoma (CCA) is a liver malignancy associated with a poor prognosis. Its main subtypes are peripheral/intrahepatic and hilar/extrahepatic CCA. Several molecular, morphological and clinical similarities between hilar/extrahepatic CCA and pancreatic ductal adenocarcinoma (PDAC) have been d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hrudka, Jan, Prouzová, Zuzana, Mydlíková, Katarína, Jedličková, Kristína, Holešta, Michal, Whitley, Adam, Havlůj, Lukáš
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262193/
https://www.ncbi.nlm.nih.gov/pubmed/34257615
http://dx.doi.org/10.3389/pore.2021.1609756
_version_ 1783719142500597760
author Hrudka, Jan
Prouzová, Zuzana
Mydlíková, Katarína
Jedličková, Kristína
Holešta, Michal
Whitley, Adam
Havlůj, Lukáš
author_facet Hrudka, Jan
Prouzová, Zuzana
Mydlíková, Katarína
Jedličková, Kristína
Holešta, Michal
Whitley, Adam
Havlůj, Lukáš
author_sort Hrudka, Jan
collection PubMed
description Cholangiocarcinoma (CCA) is a liver malignancy associated with a poor prognosis. Its main subtypes are peripheral/intrahepatic and hilar/extrahepatic CCA. Several molecular, morphological and clinical similarities between hilar/extrahepatic CCA and pancreatic ductal adenocarcinoma (PDAC) have been described. FOXF1 is a transcription factor which has been described to have prognostic significance in various tumors and it is involved in the development of bile ducts. The aim of this study is to determine occurrence of nuclear expression of FOXF1 in both subtypes of CCA and metastatic PDAC and assess its potential usefulness as a diagnostic marker. Secondary aims were to investigate the use of C-reactive protein (CRP) immunohistochemistry for diagnosing intrahepatic peripheral CCA and the significance of histological features in CCA subtypes. 32 archive specimens of CCA, combined hepatocellular carcinoma-CCA (HCC-CCA) and liver metastasis of PDAC were stained by FOXF1 and CRP immunohistochemistry and evaluated to determine histological pattern. The CCAs were classified radiologically into peripheral/intrahepatic and hilar subtype. Using Fisher exact test, we identified nuclear FOXF1 as a fairly specific (87%) but insensitive (65%) marker of hilar and extrahepatic CCA and metastatic PDAC (p = 0.005). CRP immunohistochemistry was characterized by a high sensitivity and specificity, of 79% and 88%, respectively (p = 0.001). We did not identify any histomorphological features associated with either types of CCA or metastatic PDAC. As a conclusion of novel finding, FOXF1 immunohistochemistry may be regarded as a specific but insensitive marker of hilar/extrahepatic CCA and metastatic PDAC and it may help distinguish them from peripheral CCA.
format Online
Article
Text
id pubmed-8262193
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82621932021-07-12 FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience Hrudka, Jan Prouzová, Zuzana Mydlíková, Katarína Jedličková, Kristína Holešta, Michal Whitley, Adam Havlůj, Lukáš Pathol Oncol Res Society Journal Archive Cholangiocarcinoma (CCA) is a liver malignancy associated with a poor prognosis. Its main subtypes are peripheral/intrahepatic and hilar/extrahepatic CCA. Several molecular, morphological and clinical similarities between hilar/extrahepatic CCA and pancreatic ductal adenocarcinoma (PDAC) have been described. FOXF1 is a transcription factor which has been described to have prognostic significance in various tumors and it is involved in the development of bile ducts. The aim of this study is to determine occurrence of nuclear expression of FOXF1 in both subtypes of CCA and metastatic PDAC and assess its potential usefulness as a diagnostic marker. Secondary aims were to investigate the use of C-reactive protein (CRP) immunohistochemistry for diagnosing intrahepatic peripheral CCA and the significance of histological features in CCA subtypes. 32 archive specimens of CCA, combined hepatocellular carcinoma-CCA (HCC-CCA) and liver metastasis of PDAC were stained by FOXF1 and CRP immunohistochemistry and evaluated to determine histological pattern. The CCAs were classified radiologically into peripheral/intrahepatic and hilar subtype. Using Fisher exact test, we identified nuclear FOXF1 as a fairly specific (87%) but insensitive (65%) marker of hilar and extrahepatic CCA and metastatic PDAC (p = 0.005). CRP immunohistochemistry was characterized by a high sensitivity and specificity, of 79% and 88%, respectively (p = 0.001). We did not identify any histomorphological features associated with either types of CCA or metastatic PDAC. As a conclusion of novel finding, FOXF1 immunohistochemistry may be regarded as a specific but insensitive marker of hilar/extrahepatic CCA and metastatic PDAC and it may help distinguish them from peripheral CCA. Frontiers Media S.A. 2021-04-20 /pmc/articles/PMC8262193/ /pubmed/34257615 http://dx.doi.org/10.3389/pore.2021.1609756 Text en Copyright © 2021 Hrudka, Prouzová, Mydlíková, Jedličková, Holešta, Whitley and Havlůj. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Society Journal Archive
Hrudka, Jan
Prouzová, Zuzana
Mydlíková, Katarína
Jedličková, Kristína
Holešta, Michal
Whitley, Adam
Havlůj, Lukáš
FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience
title FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience
title_full FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience
title_fullStr FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience
title_full_unstemmed FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience
title_short FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience
title_sort foxf1 as an immunohistochemical marker of hilar cholangiocarcinoma or metastatic pancreatic ductal adenocarcinoma. single institution experience
topic Society Journal Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262193/
https://www.ncbi.nlm.nih.gov/pubmed/34257615
http://dx.doi.org/10.3389/pore.2021.1609756
work_keys_str_mv AT hrudkajan foxf1asanimmunohistochemicalmarkerofhilarcholangiocarcinomaormetastaticpancreaticductaladenocarcinomasingleinstitutionexperience
AT prouzovazuzana foxf1asanimmunohistochemicalmarkerofhilarcholangiocarcinomaormetastaticpancreaticductaladenocarcinomasingleinstitutionexperience
AT mydlikovakatarina foxf1asanimmunohistochemicalmarkerofhilarcholangiocarcinomaormetastaticpancreaticductaladenocarcinomasingleinstitutionexperience
AT jedlickovakristina foxf1asanimmunohistochemicalmarkerofhilarcholangiocarcinomaormetastaticpancreaticductaladenocarcinomasingleinstitutionexperience
AT holestamichal foxf1asanimmunohistochemicalmarkerofhilarcholangiocarcinomaormetastaticpancreaticductaladenocarcinomasingleinstitutionexperience
AT whitleyadam foxf1asanimmunohistochemicalmarkerofhilarcholangiocarcinomaormetastaticpancreaticductaladenocarcinomasingleinstitutionexperience
AT havlujlukas foxf1asanimmunohistochemicalmarkerofhilarcholangiocarcinomaormetastaticpancreaticductaladenocarcinomasingleinstitutionexperience